LABORATORY NEWS
-
NAMSA Announces Strategic Acquisition Of Select Assets Of The Early Development Medical Device Testing Business Of Labcorp
NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of the Early Development medical device testing business of Labcorp (NYSE: LH), a leading provider of innovative and comprehensive laboratory services.
- Prolytix Expands Capabilities In Thrombosis And Hemostasis Testing
- Inspira Outlines Strategic Vision And Transaction Framework For Breast Cancer Liquid Biopsy Expansion
- InterVenn Biosciences Partners With Aranscia To Accelerate Commercialization Of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test
- SOPHiA GENETICS And MD Anderson Announce Strategic Collaboration To Accelerate AI-Driven Precision Oncology
ARCHIVED NEWSLETTER
- 01.06.26 -- To Fight Cancer, Gene Editing Needs To Solve Its Delivery Problem
- 12.23.25 -- Why Do So Few Cell Therapies Make The Leap From Lab To GMP?
- 12.09.25 -- What You Should Know About USP's Bioassay Updates
- 11.25.25 -- Lunit & Labcorp To Advance AI-Powered Digital Pathology Research
- 11.11.25 -- Risk-Based Analytical Method Selection In Cleaning Validation Using ASTM International Standards